Results 241 to 250 of about 314,994 (315)

A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer. [PDF]

Int J Mol Sci
Jin W, Wang M, Wang J, Fan J, Fang J, Yang G.   +5 more
europepmc   +1 more source

Targeted Delivery of Indole‐3‐Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8+ T Cell‐Mediated Immunotherapy Response in Bladder Cancer

Advanced Science, EarlyView.
A microbiota‐derived metabolite, indole‐3‐pyruvic acid, suppresses macrophage ferroptosis through the AHR–NF‐κB–SLC7A11 axis. This preserves CD8+ T cell function in bladder cancer. Macrophage‐targeted nanoparticles enhance indole‐3‐pyruvic acid delivery and overcome resistance to PD‐1 blockade.
Jianwen Lao, Xinhao Yuan, Shuai Liang, Kai Deng, Daqin Wu, Longhao Xu, Kun Zheng, Yi Lin, Peicong Cai, Haoran Zheng, Junyu Chen, Mingli Luo, Yan Chen, Xiong Chen, Chunhui Wang, Wenlong Zhong   +15 more
wiley   +1 more source

Flavones and Aminoflavones Increase the Cytotoxicity of NK Cells in Human Non-Small Cell Lung Cancer. [PDF]

J Cell Mol Med
Hsu PC, Chien CC, Cheng YJ, Chang CH, Shih TL.   +4 more
europepmc   +1 more source

Lactate‐Driven Restriction of Mitochondrial Permeability Transition Promotes Resistance to Chemo‐Immunotherapy by Suppressing Tumor PANoptosis

Advanced Science, EarlyView.
Tumor‐derived lactate establishes a metabolic lock that drives chemo‐immunotherapy resistance by suppressing PANoptosis. Mechanistically, KAT8 lactylates the mitochondrial translocator ANT2, which recruits PGAM5 to dephosphorylate CypD. This cascade restricts mitochondrial permeability transition pore opening, preventing pro‐inflammatory mtDNA leakage.
Sen Zhong, Wenlong Chen, Fanglong Liu, Shengyi Zhou, Bolin Yu, Yuying Wang, Xiqian Zhou, Xuehui Wang, Diya Liu, Zhuoyu Zhang, Xinran Wang, Mounia Lalouly, Yiwen Li, Zhefei Du, Tao Yan, Zhihui Xiao, Zhou Zhou, Huanhuan Zhu, Fengyuan Qian, Bowen Zheng, Lin Fang   +20 more
wiley   +1 more source

The metabolic environment within solid tumors drives a complex crosstalk between macrophages and NK cells. [PDF]

Front Immunol
Cakirsoy Akyoney D, Nordin J, El Andaloussi S, Alici E.   +3 more
europepmc   +1 more source

Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress

Advanced Science, EarlyView.
Working model of SLC44A2‐mediated maintenance of pDC homeostasis. This model illustrates two central mechanisms by which SLC44A2 regulates pDC homeostasis: (1) SLC44A2 limits IFN‐I production by exporting amino acids (T, N, Q), thereby preventing spontaneous pDC activation.
Ruiqun Chen, Tao Wu, Zhen Shi, Ravi Kumar Verma, Linlin Sheng, Lei Tao, Mingming Yang, Yuchen Wang, Conggang Zhang, Hao Fan, Li Wu, Ligong Chen   +11 more
wiley   +1 more source

T-bet Fate Mapping Reveals Gestational Stage-Specific Transcriptional Adaptation of Decidual NK Cells. [PDF]

Am J Reprod Immunol
Mohamed MA, Li Y, Wegrzynowicz AK, Lindner PN, Vazquez J, Lopez GE, Stanic AK.   +6 more
europepmc   +1 more source

Bioinspired Passive Flow Routing to Mitigate Thrombosis in Prosthetic Heart Valves and Cardiovascular Devices

Advanced Science, EarlyView.
Bioinspired passive flow routing mitigates thrombosis in cardiovascular devices by redirecting a small fraction of forward flow into stagnation‐prone regions. Inspired by avian alula and aircraft slat mechanisms, strategically placed routing channels restore washout around mechanical heart valves, reducing low‐shear exposure by four orders of magnitude
Yevgeniy Kreinin, Mark Epshtein, Yahel Talmon, Tirosh Mekler, Itay Or, Mahli Raad, Gil Bolotin, Josué Sznitman, Netanel Korin   +8 more
wiley   +1 more source

Integrated profiling of RUNX3 in intratumoral NK cells activity through bulk and single-cell transcriptomic analysis. [PDF]

Front Immunol
Lin G, Lin L, Zhang J, Chen L, Hu W.
europepmc   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Advanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai, Minyu Chen, Yinghan Wang, Wei Chen, Junhang Luo, Yanping Liang   +16 more
wiley   +1 more source